Company: NCEL
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065783
Chunk: 58

Company: NewcelX Ltd.
Filing Date: 2025-07-18
Form: F-4/A
Chunk 58
---
 Approval of Option and RSU Conversion on an Advisory Basis The board proposes to approve the planned conversion of outstanding options and RSUs issued by Kadimastem into equivalent securities with identical rights in Company at the time of the completion of the transactions contemplated by the Merger Agreement in the sense of an advisory vote. Date Signature Signature, if held jointly To change the address on your account, please check the box at right and indicate your new address. SPECIMEN AC:ACCT9999 90.00 REFERENCES TO ADDITIONAL INFORMATION This proxy statement/prospectus incorporates important business and financial information about NLS that is not included in or delivered with this document. You may obtain this information without charge through the Securities and Exchange Commission (the “SEC”) website ( www.sec.gov) or upon your written or oral request by contacting the Chief Executive Officer of NLS Pharmaceutics Ltd., at The Circle6, 8058 Zurich, Switzerland, or by calling +41.44.512.2150. To facilitate timely delivery of these documents, any request should be made no later than August 13, 2025 to receive them before theextraordinary meeting of shareholders of NLS (the “NLS Meeting”) . For additional details about where you can find information about NLS, please see the section entitled “ Where You Can Find More Information” in this proxy statement/prospectus. The contents of the websites of the SEC, NLS, Kadimastem, or any other entity are not being incorporated into this proxy statement/prospectus. The information about how you can obtain certain documents that are incorporated by reference into this proxy statement/prospectus at these websites is being provided only for your convenience. ABOUT THIS PROXY STATEMENT/PROSPECTUS This proxy statement/prospectus, which forms part of a registration statement on Form F -4filed with the SEC by NLS (File No. 333 -284075), constitutes a notice of meeting and proxy statement with respect to the NLS Meeting and a prospectus of NLS under Section 5 of the Securities Act of 1933, as amended, which is referred to as the Securities Act, with respect to the NLS Common Shares to be issued to Kadimastem shareholders pursuant to the Agreement and Plan of Merger, dated November 4, 2024, by and between NLS, NLS Pharmaceutics (Israel) Ltd. and Kadimastem Ltd., which was further amended on January30, 2025,